{
    "eid": "2-s2.0-85135271939",
    "title": "Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination",
    "cover-date": "2022-09-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Microbiology (medical)",
            "@code": "2726",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "AZD1222",
        "COVID-19",
        "Heterologous booster",
        "Neutralizing antibody",
        "Omicron",
        "T cells"
    ],
    "authors": [
        "Suvichada Assawakosri",
        "Sitthichai Kanokudom",
        "Jira Chansaenroj",
        "Nungruthai Suntronwong",
        "Chompoonut Auphimai",
        "Pornjarim Nilyanimit",
        "Preeyaporn Vichaiwattana",
        "Thanunrat Thongmee",
        "Thaneeya Duangchinda",
        "Warangkana Chantima",
        "Pattarakul Pakchotanon",
        "Donchida Srimuan",
        "Thaksaporn Thatsanatorn",
        "Sirapa Klinfueng",
        "Natthinee Sudhinaraset",
        "Juthathip Mongkolsapaya",
        "Nasamon Wanlapakorn",
        "Sittisak Honsawek",
        "Yong Poovorawan"
    ],
    "citedby-count": 9,
    "ref-count": 41,
    "ref-list": [
        "COVID-19 vaccine effectiveness against the Omicron (B.1.1.529) variant",
        "Neutralizing activities against the Omicron variant after a heterologous booster in healthy adults receiving two doses of CoronaVac vaccination",
        "Serum neutralisation of the SARS-CoV-2 Omicron sublineage BA.2",
        "Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis",
        "Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil",
        "SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses",
        "Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine",
        "Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)",
        "Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",
        "mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron",
        "Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant",
        "mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant",
        "Distinct antibody and memory B cell responses in SARS-CoV-2 na\u00efve and recovered individuals following mRNA vaccination",
        "Waning immunity after the BNT162b2 vaccine in Israel",
        "An mRNA vaccine against SARS-CoV-2 - preliminary report",
        "T cell memory: understanding COVID-19",
        "Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",
        "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection",
        "Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months",
        "Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine",
        "SARS-CoV-2 Omicron variant: antibody evasion and cryo-EM structure of Spike protein-ACE2 complex",
        "Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement",
        "Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial",
        "Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",
        "Rapid hypermutation B cell trajectory recruits previously primed B cells upon third SARS-CoV-2 mRNA vaccination",
        "Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination",
        "Considerable escape of SARS-CoV-2 Omicron to antibody neutralization",
        "Molecular characterisation and tracking of the severe acute respiratory syndrome coronavirus 2. Thailand, 2020-2022",
        "Spike-antibody waning after second dose of BNT162b2 or ChAdOx1",
        "SARS-CoV-2 vaccination induces immunological memory able to cross-recognize variants from Alpha to Omicron",
        "N501Y mutation of Spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2",
        "Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa",
        "Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants",
        "Three-dose vaccination elicits neutralising antibodies against Omicron",
        "Virological characteristics of SARS-CoV-2 BA.2 variant",
        "Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 variants"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60199575",
            "affilname": "Siriraj Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199575",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Oxford",
            "@id": "60026851",
            "affilname": "University of Oxford",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026851",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Pathum Thani",
            "@id": "60011947",
            "affilname": "Thailand National Center for Genetic Engineering and Biotechnology",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011947",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Oxford",
            "@id": "60008936",
            "affilname": "Nuffield Department of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008936",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Dusit",
            "@id": "127899145",
            "affilname": "Royal Society of Thailand",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/127899145",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Center of Excellence in Clinical Virology",
        "Second Century Fund",
        "Zullig pharma",
        "King Chulalongkorn Memorial Hospital",
        "Chulabhorn Royal Academy",
        "Chulalongkorn University",
        "Ministry of Public Health",
        "National Research Council of Thailand",
        "Health Systems Research Institute",
        "BIOTEC"
    ]
}